Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$13.74
-1.2%		$10.65
$2.74
▼
$15.02
$4.26B1.44.65 million shs3.70 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$227.87
+0.2%		$249.03
$186.05
▼
$282.15
$14.18B0.38875,871 shs641,433 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.39
+0.8%		$55.91
$33.76
▼
$61.14
$14.47B0.472.02 million shs1.97 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$16.75
+0.4%		$15.11
$12.07
▼
$29.23
$13.31B-1.517.17 million shs5.19 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-1.22%+8.19%+20.95%+69.42%+130.54%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.25%+1.01%-14.75%-16.99%+11.64%
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.78%+0.40%-0.24%+4.55%+41.72%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.36%+7.30%+14.73%+8.63%-18.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$13.74
-1.2%		$10.65
$2.74
▼
$15.02
$4.26B1.44.65 million shs3.70 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$227.87
+0.2%		$249.03
$186.05
▼
$282.15
$14.18B0.38875,871 shs641,433 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.39
+0.8%		$55.91
$33.76
▼
$61.14
$14.47B0.472.02 million shs1.97 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$16.75
+0.4%		$15.11
$12.07
▼
$29.23
$13.31B-1.517.17 million shs5.19 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-1.22%+8.19%+20.95%+69.42%+130.54%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.25%+1.01%-14.75%-16.99%+11.64%
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.78%+0.40%-0.24%+4.55%+41.72%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.36%+7.30%+14.73%+8.63%-18.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.67
Moderate Buy$13.38-2.66% Downside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7536.37% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.29-13.88% Downside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.53
Moderate Buy$28.6170.79% Upside

Current Analyst Ratings Breakdown

Latest ABCL, EXEL, ASND, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$18.00 ➝ $20.00
9/30/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$41.00
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00
9/29/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$17.00
9/25/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00 ➝ $43.00
9/25/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$300.00
9/24/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$13.00
9/23/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/23/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$66.17M63.67N/AN/A$3.23 per share4.25
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.45N/AN/A($2.97) per share-76.72
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.44B5.94$3.05 per share19.14$8.06 per share7.24
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.54N/AN/AN/A-248.83%-17.49%-12.36%11/9/2026 (Confirmed)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.6825.52N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.3615.701.7235.33%42.17%31.76%11/3/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest ABCL, EXEL, ASND, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.28N/AN/AN/A$0.07 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1640-$0.18-$0.0160-$0.18$7.85 million$4.05 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.77
12.77
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
562306.61 million219.53 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265797.75 million131.63 millionOptionable

Recent News About These Companies

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
October 2 at 12:07 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/summit-therapeutics-smmt-7-3-230615020.html
Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab
October 2 at 2:06 PM  |  rttnews.comhttps://www.rttnews.com/3696045/daiichi-sankyo-astrazenca-summit-partner-to-evaluate-datroway-plus-ivonescimab.aspx
Summit Therapeutics (NASDAQ:SMMT) Shares Climb 7.1% - Here's What Happened
October 2 at 7:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078640
Summit agrees to $2 billion AstraZeneca equity investment
October 2 at 6:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078180
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 2 at 2:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261001197318/en/summit-therapeutics-announces-clinical-trial-collaboration-with-astrazeneca-and-daiichi-sankyo-to-evaluate-ivonescimab-in-combination-with-trop2-directed-adc-datroway/
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
October 2 at 2:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261001131464/en/daiichi-sankyo-and-astrazeneca-enter-into-clinical-trial-collaboration-with-summit-therapeutics-to-evaluate-datroway%c2%ae-in-combination-with-ivonescimab-across-multiple-tumor-types/
What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?
October 1 at 7:45 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-summit-therapeutics-smmt-gain-220553806.html
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30 at 12:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-2-billion-vote-confidence-151701810.html
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Argenx Se (ARGX) and Obsidian Therapeutics (OBX)
September 30 at 12:52 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4883679/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-argenx-se-argx-and-obsidian-therapeutics-obx/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 7.1% - What's Next?
September 30 at 12:20 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-up-71-whats-next-2026-09-30/
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30 at 11:17 AM  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/astrazenecas-2-billion-vote-of-confidence-leaves-summit-therapeutics-trading-well-below-street-targets/?utm_source=snapi
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
September 30 at 1:03 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-apos-2-billion-investment-190315458.html
Summit Therapeutics PLC ADR (SMMT)
September 30 at 1:03 AM  |  ca.investing.comhttps://ca.investing.com/equities/summit-therapeutics-plc-news
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
September 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2997738/summit-shares-jump-on-2b-strategic-investment-from-astrazeneca?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2997738
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-still-a-buy-2026-09-29/
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
September 29, 2026  |  invezz.comI
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal
September 29, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099267?snapi
AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694521/astrazeneca-invests-2-billion-in-summit-expands-cancer-drug-collaboration-stock-up.aspx
Summit Therapeutics rises after AstraZeneca commits $2B investment
September 28, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-therapeutics-rises-after-astrazeneca-commits-2b-investment/ar-AA2d9pUc
Summit shares surge after-hours on $2 billion AstraZeneca equity deal
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/summit-shares-surge-hours-2-220826363.html
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
September 28, 2026  |  wsj.comhttps://www.wsj.com/business/astrazeneca-to-invest-2-billion-in-summit-therapeutics-collaborate-on-cancer-drugs-97d43efe

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$13.74 -0.17 (-1.22%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$13.78 +0.04 (+0.25%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$227.87 +0.56 (+0.25%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$228.00 +0.13 (+0.06%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$58.39 +0.45 (+0.78%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$58.47 +0.08 (+0.14%)
As of 10/2/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$16.75 +0.06 (+0.36%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$16.80 +0.05 (+0.27%)
As of 10/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas